Published in Am J Physiol on January 01, 1989
Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev (2005) 1.14
mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. Am J Physiol Renal Physiol (2010) 1.00
Enhanced resistance to permeability transition in interfibrillar cardiac mitochondria in dogs: effects of aging and long-term aldosterone infusion. Am J Physiol Heart Circ Physiol (2012) 0.92
Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway. J Clin Invest (1994) 0.77
The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. N Engl J Med (1992) 3.53
Flow-induced release of endothelium-derived relaxing factor. Am J Physiol (1986) 3.51
Atrial natriuretic peptide elevation in congestive heart failure in the human. Science (1986) 3.37
Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. Lancet (1993) 3.34
Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension (1996) 2.37
Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med (1991) 2.22
Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation (1998) 2.08
Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. Hypertension (2001) 2.04
Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function. Am J Physiol Renal Physiol (2001) 1.99
Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res (1993) 1.98
Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clin Proc (1995) 1.98
Noninvasive evaluation of a novel swine model of renal artery stenosis. J Am Soc Nephrol (1999) 1.96
Depression of fractional sodium reabsorption by the proximal tubule of the dog without sodium diuresis. J Clin Invest (1968) 1.90
Natriuretic peptide system in human heart failure. Circulation (1993) 1.79
Effects of synthetic atrial natriuretic factor on renal function and renin release. Am J Physiol (1984) 1.71
Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc (1992) 1.70
Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study. Heart (2009) 1.69
Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension (1998) 1.66
Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Circ Res (1988) 1.58
Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation (1990) 1.57
Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest (1989) 1.57
Endothelin in human congestive heart failure. Circulation (1994) 1.56
Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation (1995) 1.55
Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol (1990) 1.55
Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension (1995) 1.53
Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. Mayo Clin Proc (1998) 1.53
Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. J Clin Invest (1988) 1.53
Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension (2001) 1.51
Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol (1992) 1.50
Increased oxidative stress in experimental renovascular hypertension. Hypertension (2001) 1.44
Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. Am J Physiol Heart Circ Physiol (2001) 1.44
Three-dimensional microcomputed tomography of renal vasculature in rats. Hypertension (1998) 1.43
Expression of atrial natriuretic factor in the human ventricle is independent of chamber dilation. J Am Coll Cardiol (1990) 1.41
Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol (1992) 1.41
Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. Hypertension (2000) 1.37
Gender differences in hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor. Hypertension (1999) 1.36
Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol (1998) 1.32
Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol (1980) 1.31
Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc (2001) 1.29
Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol (2000) 1.28
Endothelium-derived relaxing factor inhibits renin release. Eur J Pharmacol (1988) 1.27
Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol (1992) 1.27
Effects of NG-nitro-L-arginine methyl ester on renal function and blood pressure. Am J Physiol (1991) 1.26
Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol (1993) 1.26
Adenylate kinase-catalyzed phosphotransfer in the myocardium : increased contribution in heart failure. Circ Res (1999) 1.24
Failing energetics in failing hearts. Curr Cardiol Rep (2000) 1.24
Cardiovascular and renal actions of C-type natriuretic peptide. Am J Physiol (1992) 1.23
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
High-fructose feeding elicits insulin resistance, hyperinsulinism, and hypertension in normal mongrel dogs. Hypertension (1994) 1.22
Role of the endothelium-dependent relaxing factor nitric oxide on renal function. J Am Soc Nephrol (1992) 1.22
Adrenomedullin: potential in physiology and pathophysiology. Life Sci (2000) 1.22
The natriuretic peptides in heart failure: diagnostic and therapeutic potentials. Proc Assoc Am Physicians (1999) 1.20
C-type natriuretic peptide: a selective cardiovascular peptide. Am J Physiol (1993) 1.19
Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation (1995) 1.18
Antioxidants block angiotensin II-induced increases in blood pressure and endothelin. Hypertension (2001) 1.17
Enhanced vascular reactivity during inhibition of nitric oxide synthesis in pregnant rats. Hypertension (1998) 1.16
Systemic hemodynamic and regional blood flow changes in response to chronic reductions in uterine perfusion pressure in pregnant rats. Am J Physiol Heart Circ Physiol (2007) 1.15
Effects of prostaglandins E1 and E2 on renal sodium reabsorption and Starling forces. Am J Physiol (1974) 1.15
Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int (1996) 1.15
Role of androgens in mediating hypertension and renal injury. Clin Exp Pharmacol Physiol (1999) 1.14
Computed tomography-derived intrarenal blood flow in renovascular and essential hypertension. Kidney Int (1996) 1.13
Effect of angiotensin II synthesis blockade on the hypertensive response to chronic reductions in uterine perfusion pressure in pregnant rats. Hypertension (2001) 1.12
Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens (2000) 1.12
Editorial: Site and control of phosphate reabsorption by the kidney. Kidney Int (1973) 1.10
Effect of inhibition of MAO and COMT on intrarenal dopamine and serotonin and on renal function. Am J Physiol Regul Integr Comp Physiol (2001) 1.09
A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J (1999) 1.09
Role of adenosine in contrast media-induced acute renal failure in diabetes mellitus. Mayo Clin Proc (2000) 1.07
Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail (2000) 1.07
Mechanism of adenosine-mediated decreases in glomerular filtration rate in dogs. Circ Res (1978) 1.07
The effect of indomethacin and other anti-inflammatory drugs on the renin-angiotensin system. J Clin Invest (1976) 1.07
Reduced sodium reabsorption by the proximal tubule of Doca-escaped dogs. Am J Physiol (1969) 1.07
Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep (2000) 1.06
Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. Hypertension (2001) 1.05
Intact and altered endothelium in regulation of vasomotion. Circulation (1992) 1.05
Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int (1999) 1.05
Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol (2007) 1.04
Effect of dilution and expansion of blood volume on proximal sodium reabsorption. Am J Physiol (1968) 1.04
Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. Am J Physiol (1992) 1.04
Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation (1993) 1.03
Role of renal hemodynamics and arterial pressure in aldosterone "escape". Hypertension (1984) 1.03
Risks for renal dysfunction with cardiac angiography. Ann Intern Med (1986) 1.03
C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol (1998) 1.03
Enhanced renal expression of preproendothelin mRNA during chronic angiotensin II hypertension. Am J Physiol Regul Integr Comp Physiol (2001) 1.03
Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol (2000) 1.02
Renal effects of prolonged synthesis inhibition of endothelium-derived nitric oxide. Hypertension (1992) 1.02
A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest (1995) 1.02
Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol (1997) 1.02
Effects of NG-monomethyl-L-arginine and L-arginine on acetylcholine renal response. Hypertension (1990) 1.01
Acute intrinsic renal failure induced by indomethacin: role of prostaglandin synthetase inhibition. Mayo Clin Proc (1982) 1.01
Cardiovascular, renal, and endocrine response to atrial natriuretic peptide in angiotensin II mediated hypertension. Circ Res (1986) 1.01
Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc (1991) 1.01
Role of endothelin B receptors in enhancing endothelium-dependent nitric oxide-mediated vascular relaxation during high salt diet. Hypertension (2001) 1.00
Natriuretic effect of increased proximal delivery in dogs with salt retention. Am J Physiol (1970) 1.00
Effect of vasopressin on proximal tubule sodium reabsorption in the dog. Am J Physiol (1967) 0.99
Role of peritubule Starling forces in proximal reabsorption following albumin infusion. Am J Physiol (1972) 0.99
Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol (1995) 0.99